MyMD Pharmaceuticals Enrolls First Person in Phase 2 Scientific Test of MYMD-1 as a Therapy for Delaying Aging and Increasing Healthy And Balanced Life-span
April 6, 2022
MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals (” MyMD” or “the Firm”), a clinical phase pharmaceutical business committed to extending healthy and balanced life-span, today introduced that the initial person has been enlisted in the Business’s Stage 2 medical trial of lead candidate MYMD-1, an oral immune regulator medicine, as a treatment for delaying aging and expanding healthy and balanced lifespan.
The primary endpoint for the Stage 2 double-blind, placebo-controlled clinical trial is to achieve a reduction in the circulating levels of (TNF-α), growth necrosis element receptor I (TNFRI) and IL-6. TNF-α and also IL-6 are the proteins in the body that create inflammation and also aid trigger the procedure of aging. The secondary procedures of the trial will be the safety, tolerability, as well as pharmacokinetics in this populace of patients.
” In a Stage 1 scientific trial of MYMD-1, we showed the drug’s statistically significant effectiveness in minimizing degrees of TNF-α, a key player in triggering pathological aging, in the blood. The FDA has actually approved TNF-α reduction as the primary endpoint for our Phase 2 research, which our team believe placements us well for a successful Stage 2 end result,” said Chris Chapman, M.D., President, Director as well as Chief Medical Officer of MyMD. “The initiation of person enrollment in this research breakthroughs our mission to reduce the aging procedure, protect against loss of muscle tissue in aging, restriction frailty, as well as expand healthy lifespan.”
MyMD has actually specified that there are no FDA-approved medications for dealing with aging disorders as well as extending healthy life-span human beings, a market anticipated to be at least $600 billion by 20251 according to a major investment financial institution. TNF-α blockers are the most prescribed medicines by profits, a worldwide market of about $40 billion annually,2 and also, according to Nature Aging journal,3 a slowdown in maturing that would certainly enhance life expectancy by one year deserves $38 trillion as well as by ten years deserves $367 trillion.
In addition to aging, MYMD-1’s unique action in managing the immune system and treating persistent swelling is being established for the therapy of autoimmune illness, including rheumatoid joint inflammation (RA), several sclerosis (MS), diabetes, as well as inflammatory digestive tract disease.
” We plan to begin writing procedures for a Phase 2 pilot research study of MYMD-1 for rheumatoid joint inflammation early this year,” Dr. Chapman noted. “The climbing occurrence of rheumatoid joint inflammation and also other autoimmune and also inflammatory conditions are driving demand for TNF inhibitors like MYMD-1, as well as our team believe our orally provided medication with very low toxicity would be disruptive to the $60 billion market for RA if approved by the FDA for this indication.”
Rheumatoid joint inflammation affects around 40 million people worldwide.4.
Originally created for autoimmune diseases, MYMD-1’s primary objective is to slow down the aging process, protect against sarcopenia as well as frailty, and extend healthy and balanced life expectancy. Because it can cross the blood-brain obstacle and also access to the central nervous system (CNS), MYMD-1 is also positioned to be a feasible therapy for brain-related disorders. Its system of action and efficiency in illness consisting of several sclerosis (MS) and also thyroiditis have been researched with partnerships with numerous scholastic establishments. MYMD-1 is likewise revealing assurance in pre-clinical researches as a potential therapy for article- COVID-19 issues and also as an anti-fibrotic and also anti-proliferation restorative.
MYMD-1 has revealed effectiveness in pre-clinical researches in controling the body immune system by doing as a careful inhibitor of tumor necrosis factor-alpha (TNF-α), a driver of persistent swelling. Unlike other therapies, MYMD-1 has been received these pre-clinical researches to selectively block TNF-α when it comes to be overactivated in autoimmune diseases and also cytokine tornados, yet not obstruct it from doing its typical work of being a first responder to any type of routine kind of moderate infection. MYMD-1’s simplicity of dental dosing is an additional differentiator compared to currently readily available TNF-α blockers, every one of which need delivery by shot or infusion. No approved TNF prevention has ever been dosed by mouth. On top of that, the drug is not immunosuppressive as well as has actually not been shown to cause the serious negative effects typical with typical therapies that deal with swelling.
Regarding MyMD Pharmaceuticals, Inc
. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a clinical phase pharmaceutical firm committed to expanding healthy life-span, is concentrated on developing two unique therapeutic platforms that treat the causes of condition as opposed to just attending to the symptoms. MYMD-1 is a medicine platform based upon a clinical stage tiny molecule that regulates the body immune system to regulate TNF-α, which drives chronic swelling, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being created to postpone aging, rise durability, as well as deal with autoimmune diseases as well as COVID-19- connected anxiety. The Firm’s second medicine platform, Supera-CBD, is being developed to deal with persistent pain, addiction as well as epilepsy. Supera-CBD is a novel artificial derivative of cannabidiol (CBD) and is being created to address and improve upon the rapidly expanding CBD market, that includes both FDA accepted medicines as well as CBD products not currently managed as medications. To learn more, check out www.mymd.com.